Wall Street Zen lowered shares of ALX Oncology (NASDAQ:ALXO – Free Report) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings raised ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.75.
Get Our Latest Stock Analysis on ALX Oncology
ALX Oncology Trading Down 3.7%
Institutional Investors Weigh In On ALX Oncology
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Beacon Pointe Advisors LLC purchased a new position in shares of ALX Oncology in the second quarter valued at approximately $26,000. Callan Family Office LLC acquired a new position in shares of ALX Oncology in the second quarter valued at approximately $46,000. The Manufacturers Life Insurance Company acquired a new position in shares of ALX Oncology in the second quarter valued at approximately $64,000. AXQ Capital LP purchased a new stake in ALX Oncology during the 2nd quarter worth approximately $84,000. Finally, Bank of America Corp DE increased its stake in ALX Oncology by 8.6% during the 1st quarter. Bank of America Corp DE now owns 577,783 shares of the company’s stock worth $1,158,000 after buying an additional 45,938 shares during the period. 97.97% of the stock is owned by hedge funds and other institutional investors.
ALX Oncology Company Profile
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.
Recommended Stories
- Five stocks we like better than ALX Oncology
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
